NRSN NeuroSense Therapeutics, Ltd. Expected net earnings per share growth this year
NeuroSense Therapeutics (NRSN) is developing combination therapies to combat ALS by investing in RNA regulation. The annual EPS growth trend confirms profit dynamics, where 41.80 captures the current value of the indicator. However, drug development entails high risks and intense pressure from pharma behemoths. The company's speculative advantage is based on patents, the value of which will be definitively determined following the FDA decision.
Financial and market metric breakdowns for neurosense-tx.com (NRSN)
- stock value and consensus price forecast:
- market capitalization data:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient NeuroSense Therapeutics|NRSN - Long-Term Debt to Capital|Current Liabilities to Capital NeuroSense Therapeutics Ltd.|NRSN - Company Total Debt|Debt to Net Assets Ratio NeuroSense Therapeutics|NRSN - Company Long-Term Liabilities|Amount of Current Liabilities NeuroSense Therapeutics|Intermediate Coverage Ratio neurosense-tx.com
- company profitability and valuation multiples indicators:
NRSN - Net Profit|Expected Net Profit NeuroSense Therapeutics|NRSN - Price to Earnings Ratio|Future Price to Earnings Multiple NeuroSense Therapeutics Ltd.|NRSN - PEG Multiple|EV/EBITDA Multiple NeuroSense Therapeutics|NRSN - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months NeuroSense Therapeutics|NRSN - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months neurosense-tx.com|NRSN - Net earnings per share growth this year|Earnings growth forecast for next year NeuroSense Therapeutics
Summary company analysis:NeuroSense Therapeutics, Ltd. (NRSN)
During initial screening, investors use this parameter to assess the pace of business capitalization. The metric calculates the relative change in earnings per share over a year, filtering out market noise. For NeuroSense Therapeutics (NRSN), which is preparing for the final stage of trials for its ALS drug, this indicator reflects financial stability during a period of regulatory risks. Analyzing the EPS growth percentage over 12 months allows for the differentiation of real growth from random fluctuations.
Key competitors
Earnings per share growth rate in current year Biogen Inc (BIIB)|Earnings per share growth in current year Neurocrine Biosciences Inc|Regencell Corp (RGC) - Expected net earnings per share growth this year|Earnings growth in current year AXSM|ACAD - Earnings per share growth rate in current year|Earnings per share growth in current year Xenon XENE|VKTX: Earnings per share growth this year|SUPN - Earnings per share growth in current year|Expected net earnings per share growth this year Catalyst Corp CPRX|DNLI: Earnings growth in current year|Earnings per share growth rate in current year harmonybiosciences.com (HRMY)|Net earnings per share growth this year BHVN|AMLX: Earnings per share increase in current year|Net earnings per share growth this year TRVI (Trevi Pharma)|Net earnings per one share growth for the current year PRAX|Earnings growth in current year AVXL (Anavex Life Sciences)|Earnings per share increase in current year CBLL|Prothena - Earnings growth in current year|Earnings per share growth rate in current year Alector, Inc.|Annexon Inc. (ANNX) - Earnings per share growth in current year|Omeros - Earnings per share increase in current year|NGNE (Neurogene Inc.) - Earnings growth in current year|Earnings growth in current year acimmune.com|Earnings per share growth in current year Voyager Therapeutics, Inc. (VYGR)|NMRA: Earnings per share trend in current year|Earnings growth in current year SCLX (Scilex Holding Co.)|Tevogen Bio Inc. (TVGN) - Earnings per share growth rate in current year|ACOG: Net earnings per share growth this year|CGTX - Earnings growth in current year|IKT (Inhibikase Therapeutics, Inc.) - Net earnings per share growth this year|SAVA: Net earnings per one share growth for the current year|ASRT (Assertio Holdings) - Earnings growth in current year|Coya (COYA) - Expected net earnings per share growth this year|Earnings growth in current year VTGN|Net earnings per share growth this year ovidrx.com OVID|Earnings per share growth in current year Acumen Pharmaceuticals, Inc. ABOS|Expected net earnings per share growth this year CervoMed, Inc. (CRVO)|ATHE - Earnings per share growth in current year|CLNN (Clene Inc.) - Earnings per share growth this year|pepgen.com (PEPG) - Earnings per share growth in current year|Jupiter Neurosciences, Inc. - Earnings per share increase in current year|Earnings per share growth in current year Relmada Therapeutics, Inc.|Annovis Bio Inc (ANVS) - Expected net earnings per share growth this year|Earnings per share growth in current year Grace Therapeutics, Inc. (GRCE)|Firefly Neuro - Earnings per share growth this year|Earnings per share growth in current year Klotho Neurosciences KLTO|RVPH: Earnings per share growth this year|MetaVia, Inc. - Earnings growth in current year|Earnings per share growth rate in current year NeurAxis Inc.|HSDT (heliusmedical.com) - Net earnings per share growth this year|Passage Bio (PASG) - Earnings growth in current year|Earnings per share growth in current year Neuphoria Therapeutics, Inc.|NERV: Earnings per share increase in current year|Earnings per share growth in current year Athira Pharma (ATHA)|ADXN - Earnings per share growth rate in current year|Earnings per share growth in current year Alzamend Neuro ALZN|CYCN: Earnings per share growth this year|Protagenic - Earnings growth in current year|Earnings per share growth rate in current year Pasithea Therapeutics|CRGT (cortigent.com) - Net earnings per share growth this year|Avenue Therapeutics Inc. (ATXI) - Earnings growth in current year|Earnings per share growth in current year Brainstorm Cell Therapeutics, Inc.|CARA: Earnings per share increase in current year|Earnings per share growth in current year Chromocell Therapeutics (CHRO)|ELYM - Earnings per share growth rate in current year|Earnings per share growth in current year Intra-Cellular Therapies, Inc. ITCI|Expected net earnings per share growth this year Longboard Pharmaceuticals Inc (LBPH)|Marinus - Earnings growth in current year|Earnings per share growth rate in current year NKGen Biotech Corp|NeuroBo Pharmaceuticals (NRBO) - Earnings per share growth in current year|Earnings per share growth this year SAGE|Earnings per share growth in current year Synaptogenix|Trevena Inc. (TRVN) - Expected net earnings per share growth this year|Earnings growth in current year VIGL|WENA - Earnings per share growth rate in current year|Cerevel Therapeutics - Net earnings per share growth this year
